Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure

Henry Krum; Emma Louise Ashton; Christopher Michael Reid; Victor Kalff; Jim Rogers; John Amarena; Bhuwan Singh; Andrew Maxwell Tonkin

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure

Henry Krum, Emma Louise Ashton, Christopher Michael Reid, Victor Kalff, Jim Rogers, John Amarena, Bhuwan Singh, Andrew Maxwell Tonkin

Research output: Contribution to journal › Article › Research › peer-review

96 Citations (Scopus)

Abstract

Background: Statins decrease mortality in patients with coronary artery disease. However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients. Methods and Results: We conducted a 6-month randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF]

Original language	English
Pages (from-to)	1 - 7
Number of pages	7
Journal	Journal of Cardiac Failure
Volume	13
Issue number	1
Publication status	Published - 2007

Access to Document

RM sElocation

Cite this

Krum, H., Ashton, E. L., Reid, C. M., Kalff, V., Rogers, J., Amarena, J., Singh, B., & Tonkin, A. M. (2007). Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. Journal of Cardiac Failure, 13(1), 1 - 7.

Krum, Henry ; Ashton, Emma Louise ; Reid, Christopher Michael ; Kalff, Victor ; Rogers, Jim ; Amarena, John ; Singh, Bhuwan ; Tonkin, Andrew Maxwell. / Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. In: Journal of Cardiac Failure. 2007 ; Vol. 13, No. 1. pp. 1 - 7.

@article{cb4387fce2ea44e295885905856e6ccb,

title = "Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure",

abstract = "Background: Statins decrease mortality in patients with coronary artery disease. However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients. Methods and Results: We conducted a 6-month randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF]",

author = "Henry Krum and Ashton, {Emma Louise} and Reid, {Christopher Michael} and Victor Kalff and Jim Rogers and John Amarena and Bhuwan Singh and Tonkin, {Andrew Maxwell}",

year = "2007",

language = "English",

volume = "13",

pages = "1 -- 7",

journal = "Journal of Cardiac Failure",

issn = "1071-9164",

publisher = "Elsevier",

number = "1",

}

Krum, H, Ashton, EL , Reid, CM, Kalff, V, Rogers, J, Amarena, J, Singh, B & Tonkin, AM 2007, 'Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure', Journal of Cardiac Failure, vol. 13, no. 1, pp. 1 - 7.

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. / Krum, Henry; Ashton, Emma Louise ; Reid, Christopher Michael; Kalff, Victor; Rogers, Jim; Amarena, John; Singh, Bhuwan; Tonkin, Andrew Maxwell.

In: Journal of Cardiac Failure, Vol. 13, No. 1, 2007, p. 1 - 7.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure

AU - Krum, Henry

AU - Ashton, Emma Louise

AU - Reid, Christopher Michael

AU - Kalff, Victor

AU - Rogers, Jim

AU - Amarena, John

AU - Singh, Bhuwan

AU - Tonkin, Andrew Maxwell

PY - 2007

Y1 - 2007

N2 - Background: Statins decrease mortality in patients with coronary artery disease. However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients. Methods and Results: We conducted a 6-month randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF]

AB - Background: Statins decrease mortality in patients with coronary artery disease. However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients. Methods and Results: We conducted a 6-month randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF]

UR - http://www.elsevier.com/locate/cardfail

M3 - Article

VL - 13

SP - 1

EP - 7

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 1

ER -